Valuation: Amgen Inc.

Market Cap 237B 211B 196B 177B 334B 22,394B 338B 2,347B 921B 11,771B 890B 872B 37,509B P/E 2026 *
27.9x
P/E 2027 * 24.9x
Enterprise Value 279B 248B 230B 208B 392B 26,296B 397B 2,756B 1,082B 13,822B 1,045B 1,024B 44,046B EV / Sales 2026 *
7.15x
EV / Sales 2027 * 6.76x
Free-Float
99.77%
Yield 2026 *
2.3%
Yield 2027 * 2.43%
1 day+1.12%
1 week+0.12%
Current month+4.21%
1 month+11.66%
3 months+18.77%
6 months+25.43%
Current year+30.68%
1 week 31.5
Extreme 31.5
32.53
1 month 29.58
Extreme 29.58
32.53
Current year 23.95
Extreme 23.95
32.94
1 year 23.95
Extreme 23.95
32.94
3 years 23.95
Extreme 23.95
32.94
5 years 23.95
Extreme 23.95
32.94
10 years 23.95
Extreme 23.95
32.94
Manager TitleAgeSince
Chief Executive Officer 63 01/05/2012
Director of Finance/CFO 62 13/05/2010
Chief Tech/Sci/R&D Officer 57 01/06/2023
Director TitleAgeSince
Chairman 63 01/01/2013
Director/Board Member 65 01/01/2012
Director/Board Member 71 01/01/2012
Change 5-day change 1-year change 3-year change Capi.($)
+1.12%+0.12% - - 237B
-1.01%+5.13%+58.93%+120.37% 1,144B
-0.61%+1.52%+34.34%+70.28% 625B
-1.48%+0.47%+23.08%+96.78% 511B
+0.54%+8.95%+39.45%+64.02% 377B
+1.07%+1.70%+71.06%+45.02% 366B
+0.30%+6.35%+21.84%+49.62% 291B
-0.03%+6.04%+0.40%+20.94% 262B
-0.14%+2.87%+45.56%+60.53% 237B
-1.88%+0.02%+23.77%+98.00% 194B
Average -0.36%+6.31%+35.38%+69.51% 445.32B
Weighted average by Cap. -0.45%+6.91%+40.78%+81.10%

Financials

2026 *2027 *
Net sales 38.97B 34.72B 32.15B 29.09B 54.81B 3,677B 55.46B 385B 151B 1,933B 146B 143B 6,159B 40.35B 35.96B 33.29B 30.13B 56.76B 3,808B 57.43B 399B 157B 2,002B 151B 148B 6,378B
Net income 8.55B 7.62B 7.05B 6.38B 12.02B 806B 12.16B 84.54B 33.17B 424B 32.06B 31.39B 1,351B 9.42B 8.39B 7.77B 7.03B 13.25B 889B 13.41B 93.18B 36.56B 467B 35.34B 34.6B 1,489B
Net Debt 41.36B 36.85B 34.12B 30.88B 58.17B 3,903B 58.86B 409B 161B 2,051B 155B 152B 6,537B 35.3B 31.46B 29.13B 26.36B 49.66B 3,331B 50.25B 349B 137B 1,751B 132B 130B 5,580B
Projected Income Statement - Annual - Amgen Inc.
Logo Amgen Inc.
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (95.8%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other 4.2%): primarily royalties. The United States account for 71.9% of net sales.
Employees
31,500
Date Price Change Volume
22/10/26 CA$32.46 +1.12% 3,300
20/10/26 CA$32.10 +1.26% 716
19/10/26 CA$31.70 -0.63% 1,430
16/10/26 CA$31.90 -1.60% 1,772
15/10/26 CA$32.42 +6.36% 11,160
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Amgen Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
34
Last Close Price
438.94USD
Average target price
395.67USD
Spread / Average Target
-9.86%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Amgen Inc.